Rheumatologist

I was attracted to rheumatology through exposure to excellent practicing rheumatologists early in my career.

Pharmaceutical industry payments to U.S. rheumatologists topped $220 million from 2014 through 2019, with 78% of that total going to just 6% of recipients, according to an analysis of CMS data published in Arthritis & Rheumatology.

My dad, Leonard Calabrese, DO, has emulated what it means to love what you do. He and I are longtime travel buddies and I had joined him for many American College of Rheumatology and EULAR conferences, attending more of these events — albeit not as a registered attendee — than most rheumatologists by the time I was in college.

The lobster boat tied off at the wharf. It was Ben Shipman, my rheumatoid arthritis patient, and he offered me a ride to Chebeague Island where my medical clinic was scheduled.

I applaud the authors of the 2020 American College of Rheumatology guideline for their comprehensive and thoughtful document on the management of gout.

Individuals who provide personal support for patients with rheumatoid arthritis can provide physicians with valuable insight into their physical and emotional states, according to findings published in the International Journal of Rheumatic Diseases.

Under normal circumstances, most New Yorkers thrive on being at the epicenter of civilization and culture. COVID-19 has raised the question of what happens when that civilization and culture is taken away. As residents hide out, many of them in cramped homes and studio apartments, health care workers from the biggest city in the world face challenges they have never had to face before.

These are unparalleled times indeed. We believe over the next number of weeks and months, the events unfolding now will represent a defining time for our profession and our society. As we write this in March 2020, we are approaching the maelstrom of the epidemic and bracing for events that cannot be predicted with great accuracy.

The European Commission has approved the subcutaneous formulation of Celltrion’s infliximab biosimilar for adult patients with active rheumatoid arthritis who have had an inadequate response to a prior DMARD, as well as patients with severe, active and progressive disease not previously treated with DMARDs, according to a manufacturer press release.

ATLANTA — The 2019 ACR gout guidelines call for treating patients to a target serum urate level of 6 mg/dL, a marked departure from the 2012 document, according to speakers at ACR/ARP 2019.